24(S)-Hydroxycholesterol

The brain's main cholesterol-elimination oxysterol and an endogenous NMDA-receptor positive allosteric modulator, doubling as a blood biomarker of neuronal cholesterol turnover.

As an endogenous constituent of human brain and blood, 24(S)-hydroxycholesterol is not a consumer product and carries no established dosing. Its physiological actions are concentration-dependent and biphasic: near normal tissue levels it supports NMDA receptor signaling and cholesterol efflux, whereas at high micromolar concentrations it promotes NMDA-receptor-driven excitotoxicity and non-specific oxysterol cytotoxicity in neurons and other cell types. Circulating concentrations are influenced by total body cholesterol pool, hepatic function, cholesterol-lowering therapy (statins can lower it), and the number of metabolically active neurons, so interpretation as a biomarker requires normalization and clinical context.

In disease, both elevated and reduced levels have been reported depending on stage (for example, increases early in some neurodegenerative processes reflecting turnover, and decreases with advanced neuronal loss), which complicates simple risk attribution. Therapeutic interest centers not on administering the oxysterol itself but on modulating the enzyme that makes it (CYP46A1) or on synthetic analogs designed to retain NMDA activity with a controlled pharmacokinetic and safety profile.

24(S)-Hydroxycholesterol was first isolated from human and equine brain in the mid-twentieth century and given the trivial name cerebrosterol, reflecting its neural origin. Its physiological importance became clear only after the enzyme responsible, cholesterol 24-hydroxylase, was cloned and characterized as CYP46A1 by Lund, Bjorkhem, Russell and colleagues at the end of the 1990s, establishing side-chain 24-hydroxylation as the principal exit route for brain cholesterol. In the 2000s work from the Russell laboratory using Cyp46a1 knockout mice linked brain cholesterol turnover to hippocampal long-term potentiation and learning, implicating a downstream isoprenoid (geranylgeraniol) pathway.

The molecule's second identity as a neuroactive steroid emerged in 2013, when Paul, Doherty, Zorumski and coworkers reported that 24(S)-hydroxycholesterol is a potent positive allosteric modulator of NMDA receptors, reframing a metabolic waste product as an endogenous synaptic modulator. That discovery seeded a medicinal-chemistry program at Sage Therapeutics that produced oxysterol-based NMDA positive allosteric modulators, culminating in the clinical candidate dalzanemdor (SAGE-718). In parallel, plasma 24(S)-hydroxycholesterol was developed as a translational biomarker of brain cholesterol homeostasis, and CYP46A1 activation (for example with low-dose efavirenz) advanced as a therapeutic strategy in Alzheimer's disease and related disorders.

Within neuroscience 24(S)-hydroxycholesterol is well regarded as a rare example of a molecule that bridges lipid metabolism and synaptic signaling; it is frequently described as the brain's cholesterol-elimination oxysterol and, since 2013, as one of the few endogenous positive modulators of the NMDA receptor. In clinical chemistry it is a respected but caveated biomarker of brain cholesterol turnover in Alzheimer's disease, Huntington's disease, multiple sclerosis, and other conditions. In nootropic and longevity communities it is discussed mainly indirectly, through interest in CYP46A1 activation and in its synthetic descendant dalzanemdor, rather than as a supplement, since the oxysterol itself is neither sold nor sensibly self-administered.